Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03187938 · ClinicalTrials.gov registry record
Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight
A clinical trial, sponsored by TriHealth.
- Completed
- Registry status
- 292
- Enrollment target
NCT03187938: Completed study, sponsored by TriHealth.
NCT03187938 is a clinical trial that has completed, run by TriHealth. The registered enrollment target is 292 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03187938 has completed, sponsored by TriHealth.
- COMPLETED
- Registry status
- 292 participants
- Enrollment target
Study Summary
Alkaline phosphatase is known to be produced by syncytiotrophoblasts in the placenta and its levels are normally increased in pregnancy. Therefore, it would be reasonable to hypothesize that alkaline phosphatase would be low to low normal in cases of low birth weight / intrauterine growth restriction (IUGR)/ placental insufficiency.
Primary Outcome
Birth Weight at Delivery
Interventions
- DIAGNOSTIC_TEST Testing of Alkaline Phosphatase Levels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2019-08-05 |
What the finished NCT03187938 record still lists
NCT03187938 is an observational study that tracks outcomes without assigning an intervention. The registered 292 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Testing of Alkaline Phosphatase Levels is the first listed.
NCT03187938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03187938 about?
NCT03187938 is a clinical study titled "Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight". Alkaline phosphatase is known to be produced by syncytiotrophoblasts in the placenta and its levels are normally increased in pregnancy. Therefore, it would be reasonable to hypothesize that alkaline phosphatase would be low to low normal in cases of low birth weight / intrauterine growth restrictio...
What is the current status of trial NCT03187938?
This trial is currently completed. The enrollment target is 292 participants. The study started on 2017-06-14. Estimated completion is 2019-08-05.
What interventions are being tested in trial NCT03187938?
The interventions under investigation include: Testing of Alkaline Phosphatase Levels (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03187938?
This trial is sponsored by TriHealth, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
- NCT05757102 · 292 participants · Phase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
- NCT06569667 · 292 participants · NA
Using AI and Peer Coaching to Address Racial Disparities Among People Who Use Opioids
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI